Graduated from Waseda University, and began a career in M&A advisory at the U.S.-based investment bank Houlihan Lokey. Co-founded Dioseve, Inc. in 2021 and currently serves as the company’s Representative Director.

Obtained a Doctorate degree from Azabu University, and worked as a researcher at the Child Health Institute of New Jersey, Shiga University of Medical Science, and University of Pennsylvania.
Joined Dioseve in 2023

Received a Ph.D. in Medicine from the Institute for Frontier Life and Medical Sciences at Kyoto University.
Subsequently engaged in process development, manufacturing, and medical affairs of cell products at biotech ventures and pharmaceutical companies.
Has held the current position since 2024.

Obtained a Doctorate degree from the Graduate School of Agricultural and Life Sciences, The University of Tokyo in 2018 and worked as a pharmacologist in Astellas Pharma Inc.
Joined Dioseve as Senior Scientist in 2023

Obtained a doctorate from the University of Tsukuba, and worked as a senior researcher at the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in Strasbourg and at the Institute of Agrobiological Sciences, NARO (NIAS) in Tsukuba.
Joined Dioseve in 2023.

Graduated from the Department of Biopharmaceuticals, Kyoto Pharmaceutical University.
Launched the Clinical Development Department at Eli Lilly Japan and Parexel International, and since 2015, General Manager of JConsulting Management Department.

Professor Emeritus at Kyoto University, Visiting Professor at Fujita Health University. Distinguished member and specialist in obstetrics and gynecology of the Japan Society of Obstetrics and Gynecology, distinguished member and specialist in reproductive medicine of the Japan Society for Reproductive Medicine, board member of the Japan Society of Fertilization and Implantation, honorary member of the Japan Society of Maternal Health, honorary member of the Japan Society for Sexual Science, president of the Japan Uterus Transplantation Research Society. Graduated from the School of Medicine, Nagoya University.

Obtained the degree of Ph.D. at the Faculty of Science, Kyoto University, engaged in several research areas such as neurobiology and celular biology. Joined GlaxoSmithKline Co., Ltd. in 1997 and worked in drug discovery and late phase clinical development. Appointed as an corporate officer of the company in 2011. Appointed as the Chief Scientific Officer of Bonac Corporation in 2021, engaged in the research & development in nucleic acid medicine and corporate management.